Proton and Carbon Ion Radiotherapy for Cervical Cancer

Proton and Carbon Ion Radiotherapy for Cervical Cancer : A Retrospective Analysis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05141825

Enrollment

Registered

2021-12-02

Start date

2016-01-01

Completion date

2021-10-31

Last updated

2021-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Keywords

proton and carbon ion radiotherapy

Brief summary

The aim of this study is to evaluate the toxicity and tolerance of proton and carbon ion radiotherapy (PCRT) for cervical cancer.

Detailed description

To retrospectively analyze cervical cancer patients received radical proton and carbon radiotherapy in our center. The acute and late toxicities, overall survival (OS), local control rate (LC), progression-free survival (PFS) and distant metastasis-free survival (DMFS) were analyzed.

Interventions

RADIATIONproton and carbon ion radiotherapy

proton and carbon ion radiotherapy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. . histologically diagnosis of squamous cell carcinoma of the cervix; 2. . International Federation of Gynecology and Obstetrics (FIGO) stage (2014) IB2 - IIIB, without rectum invasion; or FIGO stage IA - IB1, who refused surgery or were contraindication for surgery due to comorbidity diseases; 3. . received proton and carbon ion radiotherapy (PCRT) with or without chemotherapy for curative intention; 4. . Follow-up data available.

Exclusion criteria

1. a previous history of other malignancy; 2. squamous cell carcinoma of the cervix patients who had received surgery; 3. rectum was invaded.

Design outcomes

Primary

Measure	Time frame	Description
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	through study completion, an average of 1 year	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Secondary

Measure	Time frame	Description
overall survival rate	3 years	overall survival rate
local control rate	3 years	local control rate
progression-free survival	3 years	progression-free survival
distant metastasis-free survival	3 years	distant metastasis-free survival

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026